KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Income from Continuing Operations (2017 - 2025)

Aquestive Therapeutics has reported Income from Continuing Operations over the past 9 years, most recently at 31860000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 31860000.0 for Q4 2025, down 86.81% from a year ago — trailing twelve months through Dec 2025 was 83784000.0 (down 89.83% YoY), and the annual figure for FY2025 was 83784000.0, down 89.83%.
  • Income from Continuing Operations for Q4 2025 was 31860000.0 at Aquestive Therapeutics, down from 15446000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for AQST hit a ceiling of 8068000.0 in Q1 2023 and a floor of 31860000.0 in Q4 2025.
  • Median Income from Continuing Operations over the past 5 years was 13024000.0 (2022), compared with a mean of 13037000.0.
  • Biggest five-year swings in Income from Continuing Operations: skyrocketed 161.03% in 2023 and later tumbled 465.55% in 2024.
  • Aquestive Therapeutics' Income from Continuing Operations stood at 28945000.0 in 2021, then surged by 57.33% to 12352000.0 in 2022, then surged by 34.33% to 8111000.0 in 2023, then plummeted by 110.27% to 17055000.0 in 2024, then plummeted by 86.81% to 31860000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 31860000.0 (Q4 2025), 15446000.0 (Q3 2025), and 13548000.0 (Q2 2025) per Business Quant data.